Kornimate/medical-research-clean huggingface dataset:
bowel preparation and prokinetics in capsule endoscopy

Conditions: Small Bowel Disease; Gastrointestinal Hemorrhage; Refractory Anemia

Summary: the aim of this study is to determine whether taking bowel preparation (citramag and senna) or a medicine to speed up transit through the stomach (metoclopramide), will improve the quality of the images seen, increase the transit through the small bowel, and increase the rate of completion of capsule endoscopy. the secondary objective is to determine whether patients could routinely tolerate this bowel preparation prior to capsule endoscopy and whether the diagnostic yield of capsule endoscopy is improved.

capsule endoscopy is a diagnostic tool for the detection of small bowel disease allowing noninvasive endoscopic examination of the entire small bowel without the need for sedation. its limited battery life of 8+/-1 hours means it is paramount that the capsule reaches the caecum, visualizing the whole of the small intestine, and also that the mucosal views obtained are clear, facilitating detection of pathologic lesions. so far no optimal protocol for bowel preparation prior to capsule endoscopy has been established. recently, several studies have shown that bowel preparation with polyethylene glycol significantly reduces both gastric and small bowel transit times. similarly, visualization of the small intestine and therefore 'diagnostic yield' have both been shown to be improved by both sodium phosphate and polyethylene glycol preparation. a more recent study by selby et al also demonstrates that the prokinetic agent metoclopramide (which is known to promote emptying of the stomach) reduced both stomach and small bowel transit time, increasing completion rates from 76% to 97%). the proposal is to perform a randomised, controlled study using citramag and senna bowel preparation or metoclopramide to determine whether test completion rates are improved and whether the images of the bowel are of better quality. the hypothesis is that the improved wall visibility and increased completion rates will improve the diagnostic yield of capsule endoscopy and therefore improve patient care.

Eligibility criteria:
inclusion criteria: * patients over 18 who have been referred for capsule endoscopy exclusion criteria: * under 18 * known or suspected gastrointestinal tract obstruction as this may impede passage of the capsule * known small bowel stricture or fistula as this may impede capsule passage * pregnancy, breast feeding or phaeochromocytoma as metoclopramide is contraindicated * recent gastrointestinal surgery in view of the risk of impeded capsule passage * permanent cardiac pacemaker or implantable defibrillator in-situ to avoid the risk of possible interference * congestive cardiac failure as citramag is contraindicated in such patients

Keywords: bowel preparation capsule endoscopy randomised citramag senna metoclopramide patients referred for capsule endoscopy occult/overt gastrointestinal bleeding other suspected small bowel pathology
feasibility pilot study of internet-based cognitive behavioral therapy (cbt) for body dysmorphic disorder with global recruitment

Conditions: Body Dysmorphic Disorders

Summary: the aim of the study is to study an english-language version of bdd-net (enander, et al., 2014; enander, et al., 2016), an internet-based treatment for body dysmorphic disorder, on a globally recruited sample. this is an uncontrolled pilot study where a within-subjects repeated measures design was used to assess the feasibility of conducting all aspects of the study remotely, including recruitment, assessment, and treatment delivery.


Eligibility criteria:
inclusion criteria: * current outpatient status (not currently admitted for inpatient care) * patient is fluent in english * patient has regular access to a computer with an internet connection * patient has adequate skills to use the internet effectively. * patient provides informed consent (both verbal, and click yes to consent on secure web page) * patient is 18 years of age or older (able to provide government issued photo id) * patient has primary diagnosis of dsm-5 body dysmorphic disorder, (determined using the scid-5 module "g" which assesses diagnostic criteria on obsessive compulsive spectrum disorders) * score ≥ 4 on the body dysmorphic disorder questionnaire (bddq), * score ≥ 9 on the dysmorphic concern questionnaire (dcq) * score ≥ 20 on the body dysmorphic disorder modification of the yale brown obsessive compulsive scale (bdd-ybocs). exclusion criteria: * patient received cognitive behavior therapy for body dysmporphic disorder in the 12 months preceding treatment * patient changed psychotropic medications within the 12 weeks before treatment * patient receiving other ongoing psychotherapy at the time, * patient did not have access to a 24 hour psychiatric emergency center * patient could not provide an emergency contact person. * current substance dependence (assessed with m.i.n.i. 7.0, audit, dudit) * lifetime bipolar disorder diagnosis (assessed with m.i.n.i. 7.0 and self-report) * psychosis present * severe depression (assessed with m.i.n.i., madrs-s score ≥ 35) * personality disorder diagnosis (self-report and video-conference diagnostic interview), * lifetime history of suicide attempts (self-report) or clinically significant current suicidal ideation (≥ 5 on item 9 of madrs-s; columbia suicide severity rating scale (c-ssrs lifetime recent) - clinical version: recent (past month) - most severe ideation score ≥ 4). * additionally, eligibility continues to be assessed on an ongoing basis after initial inclusion. the madrs-s, appearance anxiety questionnaire (aai), and adverse events questionnaire (aeq) are administered weekly in order to ensure that the treatment study continues to be a safe and appropriate level of care for participants.
zenith low profile aaa endovascular graft (zlp) clinical study

Conditions: Abdominal Aortic Aneurysm; Aorto-iliac Aneurysm; Iliac Aneurysm

Summary: a prospective study conducted in japan to collect confirmatory peri-operative and 30-day information on use of the zenith lp aaa graft.


Eligibility criteria:
inclusion criteria: * abdominal aortic, aorto-iliac, and iliac aneurysms of appropriate size * vessels suitable for endovascular access and aneurysm repair exclusion criteria: * less than 20 years of age * inability or refusal to give informed consent * disease considerations that would compromise patient safety or study outcomes * unsuitable arterial anatomy

Keywords: aortic aneurysm iliac aneurysm endovascular procedures
effect of vibrating tourniquet and distraction cards on pain and anxiety in children

Conditions: Pain; Anxiety

Summary: the aim of the study was to observe the effect of the use of vibrating tourniquet and distraction card on the pain, fear and anxiety levels felt during the blood collection process in children. the study was conducted between july 2021 and march 2022 as a randomized controlled study with totally 120 children in three groups. the 'child and parent identification form' was used for socio-demographic data about the child and the parent before phlebotomy. the 'visual analog scale (vas)', 'child fear scale (cfs)' and 'child anxiety scale-state scale (ças-d)' were used before, during and after the phlebotomy. vibrating tourniquet group (intervention group 1) consists of a total of 40 children. distraction cards group (intervention group 2) consists of a total of 40 children. control group consists of a total of 40 children.


Eligibility criteria:
inclusion criteria: * the child is between the ages of 6-10, * the child has no pain just before the procedure, * the child has not taken any analgesic-effective medication in the last 6 hours, * the child does not have a hearing problem, * the child and the parent can speak and understand turkish * the child has a sufficient level of mental development to understand speech -parent and child are willing to participate in the research. exclusion criteria: * children who cannot be successfully drawn in the first application * children with oncological disease, epilepsy, migraine, or vestibular disorder.

Keywords: pain anxiety children nurse phlebotomy
haemo-autologous antegrade repriming (har) as minimum impact perfusion strategy for cardiopulmonary bypass

Conditions: Anemia; Cognitive; Disorder, Due to General Medical Condition; Embolism, Air; Transfusion; Cardiac Disease; Extracorporeal Circulation; Complications; Valve Anomalies

Summary: haemo-autologous antegrade repriming (har) is a procedure based in the combination of evidence proven measures designed to reduce the haemodilution caused by establishing the cardiopulmonary bypass (cpb) during cardiac surgery. this clinical trial aims to determinate, in one hand, the benefits related to har in terms of transfusion, icu stay, ventilation time, early mortality and complications. in the other hand analyzes the gaseous microemboli (gme) load, comparing the oxygenators venting technology´s efficiency in treatment and control group, and its relation with patient´s neurocognitive status.

har is a repriming technique based in retrograde autologous priming (rap), that has been implemented by recently recommended measures in terms of reducing blood transfusions. the expected clinical benefits are related to hemodilution´s reduction up to only 300ml. the extracorporeal circuit has been reduced to 3/8 inch diameter in both lines, reducing the surface up to 1000ml of dynamic priming. vacuum assisted venous drainage (vavd) allows to empty the venous line after priming and deairing, facilitating the venous flow for cpb initiation. the antegrade repriming eliminates the maximum amount of crystalloid contained in the circuit, displacing it to a collector bag, by using autologous blood sequestered from the arterial line to the hardshell reservoir. har reduces the cpb hemodilution related to priming from 1500 to 300 ml preventing the usual sudden haemoglobin level reduction occured during every extracorporeal techinque´s establishment. our mission is to analyze if har can be validated as a safe and effective tool to improve clinical outcomes in cardiac surgery procedures under extracorporeal circulation

Eligibility criteria:
inclusion criteria: - all patients purposed to undergo elective cardiopulmonary bypass for cardiac valve surgery or other pathologies requiring to open heart chambers. exclusion criteria: * urgency and emergency * heart transplantations * severe cognitive affection * active sepsis * previous anemia * early re-intervention * pre-op extracorporeal membrane oxygenation (ecmo) support * hemodynamic unstability during har * any clinical condition that may force protocol deviation

Keywords: retrograde autologous priming rap har cardiopulmonary bypass extracorporeal circulation gaseous microemboli perfusion
use of cysteamine in the treatment of cystinosis

Conditions: Cystinosis

Summary: cystinosis is an inherited disease resulting in poor growth and kidney failure. there is no known cure for cystinosis, although kidney transplantation may help the renal failure and prolong survival. both the kidney damage and growth failure are thought to be due to the accumulation of the amino acid cystine within the cells of the body. the cystine storage later damages other organs besides the kidneys, including the thyroid gland, pancreas, eyes, and muscle. the drug cysteamine (cystagon; procysbi) is an oral medication given to patients with cystinosis prior to kidney transplantation. the drug works by reducing the level of cystine in the white blood cells and muscle tissue. the drug may also decrease levels of cystine in the kidneys and other tissues. this study has several goals: 1. long-term surveillance of cysteamine treated patients. 2. detection of new non-kidney complications of cystinosis. 3. maintenance of a patient population for genetic testing (mutational analysis) of the cystinosis gene.\

patients with nephropathic cystinosis have been treated with the cystine-depleting agent cysteamine since 1978. this therapy prevents or delays renal deterioration, improves growth, and depletes parenchymal tissues of cystine. based largely upon data produced through this protocol, the food and drug administration approved cysteamine bitartrate for use in cystinosis patients on august 15, 1994. cysteamine is available as cystagonr through mylan pharmaceuticals in 50 mg and 150 mg capsules and as procysbir in 75 mg capsules. by virtue of the current protocol, patients are admitted to the nih clinical center for investigations every two years, except for cases of great interest or urgency. on each 1-3 day admission, a battery of tests is performed and the adequacy of cystine depletion by cysteamine is monitored. this protocol demonstrates the course of cystinosis patients treated with cysteamine, describes new complications of the disorder in poorly treated adults, and maintains nhgri expertise in the field. its monitoring and followup of patients over the course of 3 decades represents an invaluable contribution to our understanding of the natural history of this rare disease.

Eligibility criteria:
* inclusion criteria: diagnosis of cystinosis, whether classical or one of the variants with later onset or no renal complications. patients will be diagnosed as having cystinosis based upon a leucocyte cystine content greater than 1 nmol half-cystine/mg protein (normal, less than 0.2) and a typical clinical course. exclusion criteria: inability to travel to the nih. age less than one week. nonviable neonates and neonates of uncertain viability will be excluded.

Keywords: cystinosis cystine lysomal storage disease mutation analysis metabolic disease natural history
a research study of nnc0165-1562 and semaglutide in people who are overweight or obese

Conditions: Metabolism and Nutrition Disorders; Overweight or Obesity

Summary: the study is investigating new medicines for weight control in people with high body weight. the study looks at how the study medicines work in the body. participants will get semaglutide and either nnc0165-1562 or "dummy" medicine -which treatment participants get is decided by chance. participants will get 2 injections per week for 5 months. a study nurse at the clinic will inject the medicine with a thin needle in a skin fold in the stomach. the study will last for about 7 months. participants will have 27 visits to the clinic.


Eligibility criteria:
inclusion criteria: * male or female, aged 19-55 years (both inclusive) at the time of signing informed consent. * body mass index (bmi) between 27.0 and 39.9 kg/sqm (both inclusive) at screening. obesity should be due to excess adipose tissue, as judged by the investigator. exclusion criteria: * female subjects who are of child bearing potential (pre-menopausal and not surgically sterilised) and are sexually active with male partner(s) who are not surgically sterilised (vasectomy) and are not using highly effective contraceptive methods (pearl index less than 1%, such as implants, injectables, oral contraceptives, intrauterine devices, diaphragm or cervical cap+spermicide) combined with a highly effective method of contraception for their male partner(s) (e.g. condom with spermicide), or are pregnant, breast-feeding or intend to become pregnant. * male subjects who are not surgically sterilised (vasectomy) and are sexually active with female partner(s), who are not using a highly effective method of contraception (such as condom with spermicide) combined with a highly effective method of contraception for their non-pregnant female partner(s) (pearl index less than 1%, such as implants, injectables, oral contraceptives, intrauterine devices, diaphragm or cervical cap+spermicide), or intend to donate sperm in the period from screening until 3 months following administration of the investigational medical product.
echinacea junior vs vitamin c in children 4-12 years old

Conditions: Respiratory Tract Infection Viral

Summary: aim of this study is to investigate efficacy and safety of echinaforce junior tablets (250mg) in comparison with vitamin c tablets in the prevention of acute viral respiratory tract infections.

200 children aged 4-12 years are recruited by pediatricians and general practitioners and are allocated to preventive treatment with either echinaforce junior tablets or vitamin c. children take 3 x 1 tablet per day over a period of 2 months followed by 1 week treatment break and an intermediate study visit (v2). thereafter children continue with preventive treatment for another 2 months, followed by exclusion visit (v3). parents are required to contact a study coordinator at the occurrence of acute respiratory symptoms to initiate symptom recording via internet-based e-diary. on day 1 - 3 of episode parents will sample nasal secretion, which will be analysed for common respiratory agents.

Eligibility criteria:
inclusion criteria: * 4-12 years * written informed consent by parents and optionally by child * daily access to computer/email * german language skills exclusion criteria: * 13 years or older, younger than 4 years * participation in a clinical study during past 30 days * intake of antimicrobial, antiviral, immunosuppressive substances, salicylic medicaments (like aspirin) * surgical intervention 3 months prior to inclusion or planned intervention during the observation period * known diabetes mellitus * known and treated atopy or asthma * cystic fibrosis, bronchopulmonary dysplasia, chronic obstructive pulmonary disease (copd) * diseases of the immunosystem (like autoimmune disorders, degenerative illnesses (like aids or leucosis)) * metabolic or resorption disorders * liver or kidney diseases * serious health problems (e.g. neurological problems) * known allergies against compositae (e.g. camomile or dandelion) or any of the substances of the investigational product
contractile cross sectional areas and muscle strength in patients with congenital myopathies

Conditions: Inherited Muscle Diseases; Congenital Myopathy; RYR1-myopathy

Summary: patients with inherited muscle diseases can have several problems in their muscles, which can be both structural and metabolic. all the different diseases can affect the contractility of the muscles. the aim of the study is to investigate the relation between muscle strength and contractile cross sectional area (ccsa) in the thigh and calf in patients affected by inherited muscle diseases.

patients with inherited muscle diseases can have several miscellaneous problems in their muscles, which can be both structural and metabolic. depending on the specific disease multiple symptoms may be present. all the different diseases can affect the contractility of the muscles. examples of inherited muscle diseases are congenital myopathies and ryr1-myopathy, afflicting the muscle fiber structure. they are the first subgroups of inherited muscle diseases to be investigated in this study. congenital myopathies are hereditary and relatively non-progressive diseases. hypotonia is the clinical characteristic of congenital myopathies and is often presented already in the neonatal period. almost all patients have generalized muscle weakness and hypotonia. the various subtypes of congenital myopathy are a broad group of disorders defined by the predominance of particular and specific structural abnormalities shown in muscle biopsies. based on genetic and morphological features, they can be divided into four main groups; one with central cores, one with central nuclei, one with minicores and one with nemaline bodies. ryr1-myopathy is caused by a mutation in the ryr-gene. the ryr1-protein is important in the making of ryr1-receptors and channels responsible for the transport of calcium atoms within muscle cells, particularly in muscle contractions. patients typically present with limb weakness, decreased fetal movement and skeletal abnormalities. about 70% of patients with malignant hyperthermia have a mutation in the ryr1-gene. mri findings often include involvement of different muscles in the thigh and the calf.

Eligibility criteria:
inclusion criteria: * verified inherited muscle disease. * age: over 18 years old exclusion criteria: * contraindications for an mri. * claustrophobia. * pregnant or nursing women. * competing disorders (as arthritis) or other muscle disorders.

Keywords: mri ccsa contractile cross sectional area strength
a study of s6g5t-3 in the treatment of acne vulgaris

Conditions: Acne Vulgaris

Summary: to assess the efficacy of s6g5t-3 compared to its vehicle when applied once daily for 12 weeks in participants with acne vulgaris.

in this phase 3, multi-center, double-blind, randomized, vehicle-controlled, parallel-group pivotal study, participants will be admitted only after a written informed consent has been obtained and after all inclusion/exclusion criteria have been met. male and female participants at least 9 years of age with facial acne vulgaris will be eligible for enrollment for daily treatment with s6g5t-3 or its vehicle s6g5t-8, for 12 weeks.

Eligibility criteria:
inclusion criteria: 1. participant must sign an institutional review board (irb) approved written informed consent for this study. 2. male and female 9 years of age and older. 3. have 2 or fewer cysts or nodules. exclusion criteria: 1. more than 2 acne nodules or cysts (defined as an inflammatory lesion greater than or equal to 5 millimeter (mm) in diameter). 2. acne conglobata, acne fulminans, and secondary acne (for example, chloracne, drug-induced acne). 3. history of blood dyscrasia (for example, leukemia, haemophilia, sickle cell anemia, multiple myeloma). 4. underlying disease that requires the use of interfering topical or systemic therapy. 5. other dermatological conditions that require the use of interfering topical or systemic therapy or that might interfere with study assessments such as, but not limited to, atopic dermatitis, perioral dermatitis, or rosacea.

Keywords: acne vulgaris
the impact of rosuvastatin on the density score of coronary artery calcification in cad patients with diabetes mellitus

Conditions: Coronary Artery Disease

Summary: this study is designed to validate the hypothesis that the treatment of rosuvastatin could increase the score of calcification of coronary artery(cac) density in coronary artery disease(cad) patients with diabetes mellitus.cad patients with diabetes who confirmed cac will receive rosuvastatin (20mg/d) therapy for 24 months.

calcification of atherosclerotic plaque is a complicated and organic active process, which is one of the main pathologic features of atherosclerosis. widely coverage of cac is correlated with the greater likelihood of coronary events.with the increasing density of cac, the risk of cardiovascular disease (cvd) declines.some studies showed that the calcified plaque in stable chd is denser. statins are widely used in the treatment of atherosclerotic cardiovascular disease. treatment of statins may increase the density score of cac, thus, promote the unstable atherosclerotic plaque to the stable plaque.

Eligibility criteria:
inclusion criteria: 1. provision of informed consent prior to any study specific procedures 2. male and female adults aged 18-70 years old 3. chd patients without stent implantation determined by coronary angiography or coronary ct examination; 4. combined with type 2 diabetes: hba1c≥6.5%, fpg≥7.0mmol/l, 2h blood glucose≥11.1mmol/l 5. patients who confirmed cac(agatston score ≥50,measured by 64 row spiral ct6) exclusion criteria: 1. chd patients plan to recieve coronary stenting implantation or coronary artery bypass grafting; 2. patients combined with severe pulmonary, liver and kidney dysfunction 3. classed as iii-iv grade of new york heart association functional 4. pregnancy test was positive，lactation woman and in women of child-bearing potential not using appropriate contraceptive measures. 5. life expectancy within 24 months or less 6. patients combined valvular heart disease and cardiomyopathy 7. patients combined cancer 8. patients with atrial fibrillation 9. patients who is allergic to statins 10. patients with myopathy 11. patients with active liver disease